Industry Perspectives
| 4 min read
A well-chosen CDx development partner can streamline drug development, reduce delays, and pave the way for successful regulatory approval and market entry.
| 4 min read
For rare and inherited kidney diseases, genetic testing is solving the clinical trial recruitment crisis and reshaping how precision therapies get to patients.
| 1 min read
New confocal fluorescence imaging minimizes photobleaching and phototoxicity effects, capturing clear images of live 3D culture
| 2 min read
The new DMF gives developers a faster, simpler path to advance their cell therapy programs using trusted, clinical-grade starting materials.
| 2 min read
Simtra is positioned to become the first CDMO to offer commercial-scale drug product manufacturing of ADCs in the US, enabling customers to complete the entire supply chain domestically.
| 2 min read
The ABX-01 is a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains.
| 4 min read
Metabolic conditioning is emerging as a powerful strategy to enhance the potency, persistence, and manufacturability of next-generation cell therapies, providing new hope for hard to treat cancers.
| 2 min read
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema.
| 1 min read
Eppendorf Safe-Lock Tubes BioBased are made from 100 percent renewable biobased feedstock of second generation
| 2 min read
Breakthrough data validates capabilities of GlueSEEKER platform to identify novel induced protein-protein interactions and expand druggable space
| 6 min read
A domain-specific AI platform enables scientists to generate and test hypotheses faster, helping pharma teams reduce target prioritization timelines from weeks to days.
| 7 min read
Synthetic control arms are emerging as a valuable solution for clinical trials where using traditional placebo groups is difficult, unethical, or impractical.
